Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Income Statement
Quarterly Data

Bristol-Myers Squibb Co., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 11,483 11,925 11,559 11,168 10,645 10,917 11,048 11,065 10,813 11,485 11,308 11,609 11,243 11,405 10,798 10,766 10,197 9,817 10,541 7,662 5,768 6,031 5,713
Alliance and other revenues 409 276 306 309 321 309 289 341 405 402 340 376 381 298 275 302 343 312 240 283 239 242 207
Revenues 11,892 12,201 11,865 11,477 10,966 11,226 11,337 11,406 11,218 11,887 11,648 11,985 11,624 11,703 11,073 11,068 10,540 10,129 10,781 7,945 6,007 6,273 5,920
Cost of products sold, excludes amortization of acquired intangible assets (2,957) (3,267) (2,932) (2,745) (2,506) (2,876) (2,566) (2,593) (2,353) (2,720) (2,471) (2,356) (2,291) (2,452) (2,841) (2,910) (2,502) (2,699) (3,662) (2,492) (1,790) (1,972) (1,824)
Gross margin 8,935 8,934 8,933 8,732 8,460 8,350 8,771 8,813 8,865 9,167 9,177 9,629 9,333 9,251 8,232 8,158 8,038 7,430 7,119 5,453 4,217 4,301 4,096
Marketing, selling and administrative (1,983) (1,928) (2,367) (2,073) (2,003) (1,934) (1,762) (2,266) (1,930) (1,787) (1,831) (2,354) (1,788) (1,882) (1,666) (2,721) (1,706) (1,628) (1,606) (1,734) (1,055) (1,076) (1,006)
Research and development (2,374) (2,899) (2,695) (2,478) (2,242) (2,258) (2,321) (2,510) (2,418) (2,321) (2,260) (2,518) (2,980) (2,478) (2,219) (3,750) (2,499) (2,522) (2,372) (2,097) (1,378) (1,325) (1,348)
Acquired IPRD (262) (132) (12,949) (600) (80) (158) (75) (52) (30) (400) (333) (89) (271) (793) (6) (11,438)
Amortization of acquired intangible assets (2,406) (2,416) (2,357) (2,278) (2,256) (2,257) (2,256) (2,343) (2,418) (2,417) (2,417) (2,417) (2,546) (2,547) (2,513) (2,526) (2,491) (2,389) (2,282) (1,062) (25) (24) (24)
Operating income (loss) 1,910 1,559 (11,435) 1,303 1,879 1,743 2,357 1,642 2,069 2,242 2,336 2,251 1,748 1,551 1,828 (12,277) 1,342 891 859 560 1,759 1,876 1,718
Other income (expense), net (234) (273) (81) 371 258 116 413 217 140 (284) (649) (393) 409 2 702 1,826 915 736 (1,163) (689) (410) (100) 261
Earnings (loss) before income taxes 1,676 1,286 (11,516) 1,674 2,137 1,859 2,770 1,859 2,209 1,958 1,687 1,858 2,157 1,553 2,530 (10,451) 2,257 1,627 (304) (129) 1,349 1,776 1,979
Income tax (provision) benefit (461) 398 (392) 88 (203) 218 (503) 166 (601) (529) (404) 514 (605) (492) (501) 424 (379) (1,707) (462) (931) 17 (337) (264)
Net earnings (loss) 1,215 1,684 (11,908) 1,762 1,934 2,077 2,267 2,025 1,608 1,429 1,283 2,372 1,552 1,061 2,029 (10,027) 1,878 (80) (766) (1,060) 1,366 1,439 1,715
Noncontrolling interest (4) (4) (3) (6) (4) (5) (3) (2) (8) (5) (6) (6) (8) (6) (5) (9) 4 (13) (7) (5)
Net earnings (loss) attributable to BMS 1,211 1,680 (11,911) 1,762 1,928 2,073 2,262 2,022 1,606 1,421 1,278 2,372 1,546 1,055 2,021 (10,027) 1,872 (85) (775) (1,056) 1,353 1,432 1,710

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Bristol-Myers Squibb Co. revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co. operating income (loss) increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co. earnings (loss) before income taxes increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.